Envoy Medical vs Nexalin Technology
Nexalin Technology is the larger business, with $301,647 of revenue in fiscal 2025 against $241,000 for Envoy Medical (1.3 times as much). Nexalin Technology grew faster (78.8% against 7.1%). Nexalin Technology kept more of each dollar of sales as profit: a net margin of -2725.8% against -9857.3%.
| Latest fiscal year | Envoy MedicalCOCH, 2025 | Nexalin TechnologyNXL, 2025 |
|---|---|---|
| Revenue | $241,000 | $301,647 |
| Revenue growth | 7.1% | 78.8% |
| Net income | −$23.8m | −$8.2m |
| Operating margin | -9240.7% | — |
| Net margin | -9857.3% | -2725.8% |
| Return on equity | — | — |
| Free cash flow | −$18.4m | — |
| Cash | $3.7m | $654,783 |
| Total debt | $0 | $0 |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | 0.3% | — |
| Share buybacks | — | — |
| Employees | 43 | 8 |
| Market value | $712m | $32.7m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 6 buys, 0 sales | 0 buys, 0 sales |